MX2017003269A - Detección de las proteínas mal plegadas. - Google Patents

Detección de las proteínas mal plegadas.

Info

Publication number
MX2017003269A
MX2017003269A MX2017003269A MX2017003269A MX2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A
Authority
MX
Mexico
Prior art keywords
protein
misfolded
soluble
monomeric
sample
Prior art date
Application number
MX2017003269A
Other languages
English (en)
Spanish (es)
Inventor
K Vollrath Benedikt
M Lebovitz Russell
Shahnawaz Mohammad
Soto Jara Claudio
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2017003269A publication Critical patent/MX2017003269A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
MX2017003269A 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas. MX2017003269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
MX2017003269A true MX2017003269A (es) 2017-12-04

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003269A MX2017003269A (es) 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas.

Country Status (15)

Country Link
US (1) US20160077112A1 (enExample)
EP (2) EP3191599B1 (enExample)
JP (2) JP6980953B2 (enExample)
KR (1) KR102448128B1 (enExample)
CN (1) CN107208125A (enExample)
AU (1) AU2015314783B2 (enExample)
BR (1) BR112017004899A2 (enExample)
CA (1) CA2960830C (enExample)
ES (1) ES2953855T3 (enExample)
HR (1) HRP20231232T1 (enExample)
IL (2) IL251052B (enExample)
MX (1) MX2017003269A (enExample)
PL (1) PL3191599T3 (enExample)
SG (2) SG10202008464UA (enExample)
WO (1) WO2016040907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
US11079396B2 (en) * 2019-09-04 2021-08-03 Amprion, Inc. Alpha-synuclein detection using beads
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
CN110869763B (zh) 2017-05-16 2022-07-29 安培里翁公司 错误折叠tau蛋白质的检测
CA3074914A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
US20200309796A1 (en) * 2017-12-21 2020-10-01 H. Lundbeck A/S Assay, method and treatment of alpha-synucleinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
US12437843B2 (en) * 2018-09-21 2025-10-07 Gdm Holding Llc Predicting protein structures using geometry neural networks that estimate similarity between predicted protein structures and actual protein structures
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
MX2022014319A (es) * 2020-05-18 2023-02-27 Amprion Inc Sustratos de alfa-sinucleína y métodos para la fabricación y el uso de los mismos.
WO2022105923A1 (zh) * 2020-11-21 2022-05-27 浙江数问生物技术有限公司 用于检测生物样本中的错误折叠蛋白质的装置和方法
US20240192230A1 (en) * 2021-04-15 2024-06-13 The Brigham And Women’S Hospital, Inc. Digital Protein Misfolding Assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1712920T3 (da) 2000-07-07 2009-05-11 Merck Serono Sa Tidlig diagnose af konformationelle sygdomme
US20030027210A1 (en) * 2001-01-03 2003-02-06 Daniel Benjamin Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
ATE528649T1 (de) * 2005-02-15 2011-10-15 Adlyfe Inc Verfahren zum nachweis falsch gefalteter proteine und prionen
JP2009537153A (ja) * 2006-05-19 2009-10-29 アルニラム ファーマシューティカルズ, インコーポレイテッド AhaのRNAi調節およびその治療上の使用
WO2008030973A2 (en) * 2006-09-06 2008-03-13 The Board Of Regents Of The University Of Texas System Methods and compositions for the detection of protein folding disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
CN102666577A (zh) * 2009-11-24 2012-09-12 前体生物药物股份公司 诊断阿尔茨海默病或轻度认知损害的新的诊断方法
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
WO2012099884A1 (en) * 2011-01-18 2012-07-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for amplification and detection of prions
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
WO2016040903A1 (en) * 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded amyloid beta protein

Also Published As

Publication number Publication date
JP7104943B2 (ja) 2022-07-22
ES2953855T3 (es) 2023-11-16
AU2015314783A1 (en) 2017-04-27
BR112017004899A2 (pt) 2017-12-12
EP4292654A3 (en) 2024-01-03
KR102448128B1 (ko) 2022-09-27
EP4292654A2 (en) 2023-12-20
IL291809A (en) 2022-06-01
IL251052B (en) 2022-05-01
HRP20231232T1 (hr) 2024-01-19
CA2960830A1 (en) 2016-03-17
JP6980953B2 (ja) 2021-12-15
CN107208125A (zh) 2017-09-26
KR20170103741A (ko) 2017-09-13
US20160077112A1 (en) 2016-03-17
IL251052A0 (en) 2017-04-30
EP3191599B1 (en) 2023-08-02
PL3191599T3 (pl) 2023-12-27
EP3191599A1 (en) 2017-07-19
EP3191599C0 (en) 2023-08-02
AU2015314783B2 (en) 2021-10-21
SG10202008464UA (en) 2020-10-29
JP2017530373A (ja) 2017-10-12
EP3191599A4 (en) 2018-03-14
CA2960830C (en) 2023-09-05
IL291809B2 (en) 2023-06-01
SG11201701953RA (en) 2017-04-27
WO2016040907A1 (en) 2016-03-17
JP2022000629A (ja) 2022-01-04

Similar Documents

Publication Publication Date Title
MX2017003269A (es) Detección de las proteínas mal plegadas.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
PH12019550236A1 (en) Detection of misfolded tau protein
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
EP4361290A3 (en) Compositions and methods for detecting a biological contaminant
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2016209773A9 (en) Improved assays and methods for allergen detection
WO2014207049A3 (de) Verfahren zur bestimmung von proteinaggregaten unter verwendung von oberflächen-fida
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
MX2023005452A (es) Deteccion de beta amiloide por espectrometria de masas.
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
PH12017500765A1 (en) Malaria detection
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
SG10201806729VA (en) Novel assay to detect human periostin
AU2017248682A1 (en) Method for detecting and/or characterising tumour cells and associated apparatus
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
SG10201907690TA (en) Device and method for detecting target molecules
SG10201901836PA (en) Test strip assembly
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
WO2014145243A3 (en) High resolution melting analysis assay for the detection of viral dna